BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 29761307)

  • 1. Intravesical bacillus Calmette-Guerin therapy after second transurethral resection for primary T1 bladder cancer.
    Baba M; Kageyama S; Yoshida T; Fujiwara R; Kim CJ; Takimoto K; Nagasawa M; Soga H; Nagatani Y; Nishikawa Z; Kawauchi A
    Int J Clin Oncol; 2018 Oct; 23(5):951-956. PubMed ID: 29761307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bacillus Calmette-Guerin therapy after the second transurethral resection significantly decreases recurrence in patients with new onset high-grade T1 bladder cancer.
    Iida K; Naiki T; Kawai N; Etani T; Ando R; Ikegami Y; Okamura T; Kubota H; Okada A; Kohri K; Yasui T
    BMC Urol; 2016 Feb; 16():8. PubMed ID: 26920373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is intravesical Bacillus Calmette-Guérin therapy superior to chemotherapy for intermediate-risk non-muscle-invasive bladder cancer? An ongoing debate.
    Han KS; You D; Jeong IG; Kwon T; Hong B; Hong JH; Ahn H; Ahn TY; Kim CS
    J Korean Med Sci; 2015 Mar; 30(3):252-8. PubMed ID: 25729246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of time to second transurethral resection on oncological outcomes of patients with high-grade T1 bladder cancer treated with intravesical Bacillus Calmette-Guerin.
    Calò B; Falagario U; Sanguedolce F; Veccia A; Chirico M; Carvalho-Diaz E; Mota P; Lima E; Autorino R; Carrieri G; Cormio L
    World J Urol; 2020 Dec; 38(12):3161-3167. PubMed ID: 32062805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guérin.
    Sfakianos JP; Kim PH; Hakimi AA; Herr HW
    J Urol; 2014 Feb; 191(2):341-5. PubMed ID: 23973518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of the interval between first and second transurethral resection on recurrence and progression rates in patients with high-risk non-muscle-invasive bladder cancer treated with maintenance intravesical Bacillus Calmette-Guérin.
    Baltacı S; Bozlu M; Yıldırım A; Gökçe Mİ; Tinay İ; Aslan G; Can C; Türkeri L; Kuyumcuoğlu U; Mungan A
    BJU Int; 2015 Nov; 116(5):721-6. PubMed ID: 25715815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer.
    Shelley MD; Kynaston H; Court J; Wilt TJ; Coles B; Burgon K; Mason MD
    BJU Int; 2001 Aug; 88(3):209-16. PubMed ID: 11488731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival.
    Shahin O; Thalmann GN; Rentsch C; Mazzucchelli L; Studer UE
    J Urol; 2003 Jan; 169(1):96-100; discussion 100. PubMed ID: 12478112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravesical Bacillus Calmette-Guerin in Ta and T1 Bladder Cancer.
    Shelley MD; Court JB; Kynaston H; Wilt TJ; Fish RG; Mason M
    Cochrane Database Syst Rev; 2000; 2000(4):CD001986. PubMed ID: 11034738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for intravesical recurrence in patients with high-grade T1 bladder cancer in the second TUR era.
    Takaoka E; Matsui Y; Inoue T; Miyazaki J; Nakashima M; Kimura T; Oikawa T; Kawai K; Yoshimura K; Habuchi T; Ogawa O; Nishiyama H
    Jpn J Clin Oncol; 2013 Apr; 43(4):404-9. PubMed ID: 23444116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer.
    Koie T; Ohyama C; Hosogoe S; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Mori K
    Int Urol Nephrol; 2015 Sep; 47(9):1509-14. PubMed ID: 26149637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Results of treatment of superficial vesical tumors by transurethral resection alone and transurethral resection followed by an intravesical instillation of Calmette-Guerin bacillus].
    Chopin D; Hoznek A; Colombel M; Surig-Biscarat MH; Antiphon P; Hervé JM; Bellot J; Auvert J; Abbou CC
    Ann Urol (Paris); 1990; 24(5):435-40. PubMed ID: 2252358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single monthly bacillus Calmette-Guérin intravesical instillation is effective maintenance therapy to prevent recurrence in Japanese patients with non-muscle-invasive bladder cancer.
    Okamura T; Akita H; Ando R; Ikegami Y; Naiki T; Kawai N; Tozawa K; Kohri K
    Int J Clin Oncol; 2012 Oct; 17(5):477-81. PubMed ID: 21947596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of tumor-free status in repeat resection before intravesical bacillus Calmette-Guerin for high grade Ta, T1 and CIS bladder cancer.
    Guevara A; Salomon L; Allory Y; Ploussard G; de la Taille A; Paul A; Yiou R; Hoznek A; Dahan M; Abbou CC; Vordos D
    J Urol; 2010 Jun; 183(6):2161-4. PubMed ID: 20399454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second transurethral resection and prognosis of high-grade non-muscle invasive bladder cancer in patients not receiving bacillus Calmette-Guérin.
    Angulo JC; Palou J; García-Tello A; de Fata FR; Rodríguez O; Villavicencio H
    Actas Urol Esp; 2014 Apr; 38(3):164-71. PubMed ID: 24613147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
    Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J
    Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bacillus Calmette-Guérin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study.
    Duchek M; Johansson R; Jahnson S; Mestad O; Hellström P; Hellsten S; Malmström PU;
    Eur Urol; 2010 Jan; 57(1):25-31. PubMed ID: 19819617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrence of primary superficial bladder cancer treated with prophylactic intravesical Tokyo 172 bacillus Calmette-Guérin: a long-term follow-up.
    Shinka T; Matsumoto M; Ogura H; Hirano A; Ohkawa T
    Int J Urol; 1997 Mar; 4(2):139-43. PubMed ID: 9179686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insignificant role of bacillus Calmette-Guérin maintenance therapy after complete transurethral resection of bladder tumor for intermediate- and high-risk non-muscle-invasive bladder cancer: Results from a randomized trial.
    Nakai Y; Anai S; Tanaka N; Chihara Y; Haramoto M; Otani T; Nakagawa Y; Hirao Y; Konishi N; Fujimoto K
    Int J Urol; 2016 Oct; 23(10):854-860. PubMed ID: 27416975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Intravesical Bacilli Calmette-Guerin Therapy After Second Transurethral Resection in Stage Ta T1 High-Grade Bladder Cancer.
    Kimura Y; Honda M; Morizane S; Hikita K; Isoyama T; Ono K; Koumi T; Takahashi C; Takenaka A
    Yonago Acta Med; 2019 Jun; 62(2):191-197. PubMed ID: 31320823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.